RxDoctor Payments Data

Ramesh Brahmbhatt, MD

Interventional Cardiology · Miramar Beach, FLNPI 1750489977

Payments from drug & device makers

$23,705in general payments, 2019–2025

Across 294 payments — averaging $80.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$18K
  • Boston Scientific$1K
  • AstraZeneca$501
  • Abiomed$470
  • Boehringer Ingelheim$384
  • Novartis$369
  • plus $3K from 19 others

What the payments were for

  • Speaking & faculty fees$15,50065%
  • Travel & lodging$2,44810%
  • Food & beverage$5,72624%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,705 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$125,824
Medicare patients
605
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$236,660
EntrestoSacubitril/Valsartan126$118,805
XareltoRivaroxaban37$41,285
JardianceEmpagliflozin32$28,183
MultaqDronedarone Hcl11$16,084
BrilintaTicagrelor18$15,688
Repatha SureclickEvolocumab12$10,135
NexlizetBempedoic Acid/Ezetimibe12$6,425
Ranolazine ErRanolazine34$5,154
Potassium Chloride28$4,561
Metoprolol Succinate284$3,760
Rosuvastatin Calcium126$1,831
Diltiazem 24hr Er (Cd)Diltiazem Hcl52$1,597
Flecainide Acetate38$1,509
ClopidogrelClopidogrel Bisulfate91$1,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$236,660194 claims
NovartisEntresto$369$118,805126 claims
Johnson & JohnsonXarelto$17,945$41,28537 claims
Boehringer IngelheimJardiance$384$28,18332 claims
Sanofi-aventis U.S. LLCMultaq$54$16,08411 claims
AstraZenecaBrilinta$501$15,68818 claims
Esperion Therapeutics, Inc.Nexlizet$288$6,42512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miramar Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →